Learning Hub

< BACK Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms Feb 4, 2026 New iPROLEPSIS publication presents the co-design of exergames to support physical activity and rehabilitation in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . Psoriatic arthritis (PsA) is a rheumatic disease affecting the skin and joints and is commonly associated with stiffness, impaired mobility, and chronic pain. In addition to biological treatments, physiotherapy and exercise are often recommended to improve range of motion and physical function. However, low adherence, high costs, and limited engagement frequently reduce the effectiveness of these interventions. The paper presents the design of two exergames – The Spy and Zen Forest – developed as accessible digital tools to complement traditional rehabilitation approaches. Exergames embed therapeutic movements into game mechanics, supporting motivation and consistency in physical activity. Both games were co-designed with 29 experts , including patients with psoriatic arthritis, clinicians, researchers, and technical stakeholders, to ensure alignment with clinical goals, patient needs, and safe physical engagement. In The Spy , players complete physically engaging missions designed to stimulate dynamic body movement and support coordination, mobility, balance, strength, and flexibility. Zen Forest focuses on slow, calm stretching routines inspired by Pilates and Yoga, promoting flexibility, relaxation, and body awareness. Together, the exergames aim to support personalised activity routines and enable clinicians to monitor progress and recommend tailored interventions. Read the full publication: https://zenodo.org/records/18468928 iPROLEPSIS_Zen and Spy.png iPROLEPSIS_Zen and Spy.png 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How is psoriatic arthritis treated? Non-pharmacological treatments See related Handbook section PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 10 Nov 6, 2025 Latest News from iPROLEPSIS Welcome to the tenth edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. iPROLEPSIS project newsletter Issue No. 10_Nov 2025 .pdf Download PDF • 9.31MB Newsletter 10 cover for article.png Newsletter 10 cover for article.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at Faculdade de Motricidade Humana PhD Seminar Dec 4, 2025 Lecture on recent findings shared with PhD students On 20 November 2025 , iPROLEPSIS was presented at Faculdade de Motricidade Humana (FMH) during the PhD seminar “Métodos de Investigação Avançada em Motricidade Humana”. Sofia Balula Dias spoke to more than 20 PhD students , presenting key findings from the project’s most recent publications and ongoing research on psoriatic arthritis. The session was an opportunity to share current scientific work and answer questions from the students. Slide1.JPG Slide2.JPG Slide8.JPG Slide1.JPG 1/8 PREVIOUS NEXT

< BACK iPROLEPSIS presented at MEDICA 2023 Nov 14, 2023 iPROLEPSIS project presented at the world’s largest event for the medical sector Project partners Amalia Ntemou ( Netcompany-Intrasoft ) and Georgios Apostolidis ( Aristotle University of Thessaloniki (AUTH) ) presented the iPROLEPSIS project at the MEDICA - Leading International Trade Fair in Germany. MEDICA is the world’s largest event for the medical sector. It attracts several thousand exhibitors from more than 50 countries in the halls. Furthermore, each year, leading individuals from business, research, and politics grace this top-class event with their presence. MEDICA 2023 took place on 13-16 November in Düsseldorf, Germany. IMG_20231115_135346.jpg IMG_20231115_135346.jpg 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How is psoriatic arthritis diagnosed? See related Handbook section PREVIOUS NEXT

< BACK iPROLEPSIS digital ecosystem's architecture Oct 5, 2023 iPROLEPSIS ecosystem's architecture: a glimpse into technical progress One of the main objectives of the iPROLEPSIS project is to provide a digital health ecosystem to support healthcare professionals in disease screening, monitoring, and treatment while empowering individuals with/at risk of Psoriatic Arthritis with personalised insights and preventive interventions. In September 2023, the project’s technical partners introduced the first version of the iPROLEPSIS ecosystem architecture , including the initial technical specifications and product backlog. __________________ Amalia Ntemou from Netcompany-Intrasoft , consortium partner leading technical specification, system architecture and product backlog task within iPROLEPSIS, shares insights on the latest updates on the iPROLEPSIS ecosystem architecture. The first version of the iPROLEPSIS ecosystem's architecture and technical specifications has been defined. Can you explain the importance of this achievement in the project's development process? One of the main objectives of the iPROLEPSIS project is to provide a digital health ecosystem to support healthcare professionals in disease screening, monitoring, and treatment, while empowering individuals with/at risk of PsA with personalised insights and preventive interventions. The design of the architecture and the definition of functional and non-functional requirements are essential for the successful implementation of the iPROLEPSIS ecosystem as it constitutes a clear and comprehensive guide for partners’ development efforts. Various systems’ elements, components, connectors, processes and interactions are illustrated thereby enabling common understanding among project’s partners and adherence to common approaches and specifications that promote effective collaboration and delivery. A well-defined architecture with clear functional and non-functional requirements can be the basis for delivering sustainable solutions. What are the main components of the iPROLEPSIS digital ecosystem to be developed? The initial conceptual architecture of the iPROLEPSIS ecosystem consists of the miPROLEPSIS patient mobile app (including the embedded subcomponent/feature biAURA), the iPROLEPSIS healthcare professionals (HCP) web app , the cloud-based Data Management System , the AI-driven Lifestyle Recommendation Engine , the xAI-driven Models Engine and the Serious Games Suite . Finally, the operation of the entire system is supported by the Orchestration and Monitoring component . For whom is the iPROLEPSIS ecosystem specifically intended, and how does it cater to their unique needs? Patients are the primary users of the miPROLEPSIS patient app which is the tool for personalised disease monitoring. The miPROLEPSIS patient app operates as a tool for capturing data from sensors and wearable devices, as well as communicating feedback from the recommendation engine to the user. The miPROLEPSIS patient app incorporates additional applications/features (e.g., biAURA, keyboard etc.) for further monitoring of patients’ conditions, interventions and engagement hooks. Via the miPROLEPSIS HCP app, doctors and health care professionals are able to track their patients’ health status, review projections of the PsA progression, and utilise recommendations of optimised personalised suggestions towards a better management of PsA. Aggregated patients’ data about their health status, and outcomes of the xAI Models Engine are displayed intuitively and informatively to HCPs through dashboards. Doctors can monitor patients’ adherence to medical, dietary, and physical activity plans and issue warnings and notifications or adjust treatment regimens. In this way, accurate interventions are supported, while efficient and optimized management of PsA patients’ needs can be achieved and communicated to fellow colleagues and related stakeholders. What was the main focus while designing the iPROLEPSIS ecosystem architecture? The iPROLEPSIS digital health ecosystem serves as the enabler for personalised preventive care and the empowerment of citizens, patients and Healthcare Professionals (HCP). This emphasis on personalisation and empowerment guided the collection and definition of functional and non-functional requirements, as well as the internal architecture of components and technical specifications. Ultimately, these efforts led to the design of the ecosystem’s architecture. Have any methodologies been used in designing the iPROLEPSIS ecosystem architecture, and why is it important to use them? To organise the design and architecture of the iPROLEPSIS ecosystem, several established frameworks/methodologies were evaluated based on a thorough literature review in order to conclude to a framework that provides a holistic and comprehensive view of a software system’s architecture. Finally, we used a widely known methodology developed in 1995 by Kruchten , due to its ability to offer a structured approach to the system’s design, enabling multidisciplinary teams to represent different aspects of the system effectively and in detail. Utilising already established methodologies and following best practices, enhances efficiency, reduces risks, leads in better design decisions and contributes to overall success of the project. As the project progresses, how will the architecture and product backlog be refined and adapted during the development phases of the iPROLEPSIS? Development and establishment of the iPROLEPSIS digital health ecosystem is an ongoing process that runs approximately until the end of the project. Technical testing and verification of new versions of ecosystem’s components, as well as the monitoring of their performance and stability once released to users, have also been considered. The outcomes of development and monitoring processes will continuously populate the product backlog, representing the changing needs and priorities as the development of the components progresses. All updates and enhancements will lead to a refined version of the architecture and a fully operational iPROLEPSIS ecosystem. Stay tuned as we embark on this transformative journey towards a brighter future in Psoriatic Arthritis management! News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Seasons Greetings from iPROLEPSIS Dec 23, 2025 Happy holidays and best wishes for the year ahead! We wish you a warm and peaceful holiday season. May the coming year bring good health, positive moments, and new opportunities. Happy holidays! iPROLEPSIS iPROLEPSIS Happy Holidays.png iPROLEPSIS Happy Holidays.png 1/1 PREVIOUS NEXT

< BACK World Psoriasis Day 2025: Advancing Prevention and Care Oct 29, 2025 On World Psoriasis Day, iPROLEPSIS highlights ongoing efforts to improve early detection, prevention, and digital support for people living with psoriasis and psoriatic arthritis October 29 marks World Psoriasis Day – a day dedicated to raising awareness of the impact psoriasis has on millions worldwide. For many, the condition goes beyond the skin: up to 30% develop psoriatic arthritis , an inflammatory disease that causes joint pain, stiffness, and fatigue, significantly affecting daily life. This year’s World Psoriasis Day video shares how iPROLEPSIS is working to advance psoriatic arthritis prevention and care. Through clinical studies, digital biomarkers, and co-created digital health tools, the project aims to support early detection , timely monitoring , and personalised care . The ongoing PDPID study is developing and validating predictive models for psoriatic arthritis progression, while the iPROLEPSIS digital ecosystem – including the miPROLEPSIS apps, miDashboard for professionals, and lifestyle interventions – is designed together with patients and clinicians to make technology more supportive of everyday care. Its tools – the miPROLEPSIS and miPROLEPSIS-Lite apps, the miDashboard for professionals, and lifestyle interventions such as serious games and personalised recommendations – are co-created with patients and healthcare providers to ensure they are practical, easy to use, and truly supportive of everyday care. On this World Psoriasis Day, iPROLEPSIS stands with everyone living with psoriasis and psoriatic arthritis. Together with clinical and research partners across Europe, the project continues to work toward earlier detection, prevention, and innovative digital solutions to improve lives. Watch the World Psoriasis Day 2025 video here: Screenshot 2025-10-29 083418.png Screenshot 2025-10-29 083418.png 1/1 PREVIOUS NEXT

< BACK British Society for Rheumatology Annual Conference 2024 Apr 26, 2024 Dr. Laura Coates Addresses Psoriasis to Psoriatic Arthritis Transition British Society for Rheumatology Annual Conference, the UK’s leading rheumatology event, took place on 24-26 April 2024. Dr Laura Coates discussed preventing the transition of psoriasis to psoriatic arthritis, including the evidence so far and studies underway with iPROLEPSIS and HIPPOCRATES IMI . Laura Coates_BRC 2024.jfif Laura Coates_BRC 2024.jfif 1/1 PREVIOUS NEXT

< BACK Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers Oct 30, 2024 The qualitative study exploring the perspective of psoriatic arthritis (PsA) patients towards the digital biomarkers (dBMs) Latest research initiative under the iPROLEPSIS project: Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers Abstract Objectives The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). Methods As part of a Design Thinking approach, six focus groups were conducted involving 27 PsA patients. The semistructured topic guide included disease activity, coping strategies, care needs, and potential advantages and disadvantages of dBMs. Thematic analysis followed an abductive coding method. Results PsA daily permeates patients’ lives, both physically and mentally. Participants discussed how their lives are focused on minimising the impact of the disease on their daily routines. Their attempts to gain control over their disease highly depend on trial and error. Flare-ups are related to physiological as well as behavioural micro and macro changes. Understanding these changes could enable the detection of (early) flare. Participants elicited pros and cons of the use of dBMs, discussed their intended use and made practical remarks. This led to three main themes: ‘Perceived dBM opportunities’, ‘Mapping Disease activity’ and ‘Perceived dBM barriers and pitfalls’. Conclusion PsA patients are receptive to dBMs for tracking the disease symptoms. Disease activity is regarded multifaceted and thus, dBMs should include a broad range of features to truly reflect the disease activity status. Reducing the time of trial and error in learning to manage the disease is regarded beneficial. Establishing and maintaining the relationship with their attending physicians is a prerequisite, even if remote patient monitoring becomes an alternative for some physical hospital visits. Read the full publication in RMD Open: https://rmdopen.bmj.com/content/10/4/e004699 Digital biomarkers for psoriatic arthritis a qualitative focus groups study on patient-per .pdf Download PDF • 1.55MB 1/1 PREVIOUS NEXT

< BACK Maximising Project Impact: iPROLEPSIS Exploitation Strategy Seminar with Horizon Results Booster Jun 27, 2024 Maximising Project Impact: Effective Exploitation Strategies On 26 June 2024, iPROLEPSIS held an online Exploitation strategy seminar led by Horizon Results Booster expert Emmanuel Sofianopoulo. The seminar focused on introducing consortium partners to exploitation concepts and helping to develop an exploitation strategy for project results. Key points covered included: Introduction to exploitation and exploitation plans, Key Exploitable Results (KER), and the difference between exploitation and dissemination. We also participated in a workshop for a specific KER, involving: A session to introduce the KER. Further development and refinement of the Characterisation Table, risk map and outlining the Exploitation Roadmap. Excited to apply these strategies as we move forward with our project goals! 1/8 PREVIOUS NEXT